Trials 8 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 13 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06777732 Background | Mar → Sep 2025 overdue | Helicobacter pylori infectious disease | Nanjing First Hospital, Nanjing Medical University | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06823791 Background | Aug 2022 → Jul 2024 | Helicobacter pylori infectious disease | Liaocheng People's Hospital | Completed | No outcome recorded |
| Phase 49 trials | ||||||
| Phase 4 | NCT05647278 Comparator | Nov 2023 → Sep 2025 | Helicobacter pylori infectious disease | Zhang Xiaofeng,MD | Completed | No outcome recorded |
| Phase 4 | NCT06168214 Comparator | Sep 2023 → Nov 2024 overdue | — | Xijing Hospital of Digestive Diseases | Recruiting | No outcome recorded |
| Phase 4 | NCT05419674 Comparator | Aug 2022 → Aug 2023 | Helicobacter pylori infectious disease | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 4 | NCT05431075 Background | Jul 2022 → Feb 2024 | Helicobacter pylori infectious disease | Shandong University | Completed | No outcome recorded |
| Phase 4 | NCT04558502 Background | Jan → Jun 2022 | — | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 4 | NCT04907747 Background | May 2021 → Apr 2022 | Helicobacter pylori infectious disease | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 4 | NCT03658746 Background | Jan → Dec 2019 | Helicobacter pylori infectious disease | Shandong University | Completed | No outcome recorded |
| Phase 4 | NCT03658733 Background | Dec 2018 → Aug 2019 | Helicobacter pylori infectious disease | Shandong University | Unknown | No outcome recorded |
| Phase 4 | NCT02988089 Background | Apr → Sep 2017 | Helicobacter pylori infectious disease | Shandong University | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT07533422 Comparator | May → Dec 2026 expected | Helicobacter pylori infectious disease | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| — | NCT04723472 Background | Aug 2023 → Dec 2025 | Helicobacter pylori infectious disease | Shanghai East Hospital | Suspended | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 21 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Colloidal bismuth pectin | “esomeprazole (20 mg, twice daily), colloidal bismuth pectin (150 mg, four times daily), clarithromycin (500 mg, twice daily), and amoxicillin (1.0 g, twice daily) for 14 days” NCT05549115 ↗20“esomeprazole magnesium 20 mg bid +colloidal bismuth pectin 200mg bid + amoxicillin 1000 mg bid + furazolidone 100 mg bid, for 14 days.” NCT06823791 ↗ “Conventional Quadruple Therapy： Vonoprazan 20mg BID; Colloidal Bismuth Pectin 220mg BID; Amoxicillin 1.0g BID; tetracycline 0.5g TID.” NCT07533422 ↗ “The regimen contains rabeprazole 20mg bid, colloidal bismuth pectin 200mg bid, and two sensitive antibiotics determined by AST.” NCT03565484 ↗ “H. pylori eradication therapy comprising esomeprazole, amoxicillin,clarithromycin and colloidal bismuth pectin.” NCT02933229 ↗ “Colloidal Bismuth Pectin 200mg bid po” NCT04723472 ↗ “colloidal bismuth pectin 300mg bid” NCT06168214 ↗ |
| Route | Oral | “Colloidal Bismuth Pectin 200mg bid po” NCT04723472 ↗ |